Navigation Links
Pearl Therapeutics Appoints Howie Rosen to Board of Directors
Date:11/23/2009

REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors. Mr. Rosen has 25 years of experience in the pharmaceutical and biotechnology industries, including key roles at Gilead Sciences and ALZA Corporation. His appointment increases the number of directors on Pearl's Board to six.

"Howie brings a wealth of product development, commercialization and general management experience to Pearl, having held senior positions at some of the leading companies in the industry," said Perry Karsen, Chief Executive Officer of Pearl Therapeutics. "His proven track record in the drug delivery market will be invaluable to Pearl as we advance our proprietary products toward late-stage development for the treatment of chronic obstructive pulmonary disease."

"I look forward to working with Pearl's Board and management team to help develop and commercialize their very promising products for the treatment of serious, highly prevalent respiratory diseases," said Mr. Rosen. "Because of Pearl's distinctive technology platform, their products have the potential to offer patients and clinicians many compelling advantages over currently available therapies."

Mr. Rosen is currently a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies, most recently as President of the ALZA division of Johnson & Johnson. During his tenure at ALZA, he was responsible for product development activities, portfolio management, corporate and new product planning, mergers and acquisitions, R&D planning and technology ventures. Prior to ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., served as Director of Corporate Development at GenPharm International, Inc., and was a consultant in the San Francisco office of McKinsey & Co.

Mr. Rosen also serves on the Boards of Directors of AcelRx Pharmaceuticals, Inc., PaxVax, Inc. and CNS Therapeutics, Inc.

He holds an M.B.A. from the Stanford Graduate School of Business, an M.S. in chemical engineering from the Massachusetts Institute of Technology, and a B.S. in chemical engineering from Stanford University. He is a member of the National Academy of Engineering.

About Pearl Therapeutics

Pearl Therapeutics is developing therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures. For more information, please visit us at http://www.pearltherapeutics.com.

SOURCE Pearl Therapeutics Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
5. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
6. Pearl Therapeutics Secures $8 Million in Debt Financing
7. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):